Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.57 USD | +1.77% | +0.91% | +51.81% |
03/05 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
02/05 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.81% | 2.33B | |
+22.56% | 44.96B | |
+0.66% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+11.09% | 26.08B | |
-21.45% | 19.03B | |
+6.14% | 12.75B | |
+28.78% | 12.06B | |
-3.59% | 11.75B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target